Welcome to our dedicated page for Identa Rvice news (Ticker: IDTA), a resource for investors and traders seeking the latest updates and insights on Identa Rvice stock.
Identa Ltd Rvice (IDTA) delivers critical detection solutions for security and consumer markets through advanced forensic testing technology. This news hub provides authorized updates directly from the company, serving as the definitive source for stakeholders monitoring its operational and market developments.
Access real-time updates on product innovations, regulatory milestones, and strategic partnerships that drive IDTA's leadership in narcotics detection and diagnostic kits. Our curated feed includes earnings reports, manufacturing updates, and distribution network expansions essential for evaluating corporate health.
Key news categories cover product launches in forensic technology, financial performance updates, regulatory compliance achievements, and global distribution partnerships. Each update undergoes verification to ensure alignment with market disclosure standards.
Bookmark this page for streamlined access to IDTA's official communications. Combine our updates with third-party analysis through Stock Titan's research tools for comprehensive investment evaluation.
IDenta Corp. (OTCQB: IDTA) will hold its 2022 Annual Shareholders' meeting on June 26, 2022, at 7:00 PM (GMT +3) in Jerusalem, Israel. The company specializes in developing Field Detection and Home Diagnostic Testing Kits for Narcotics, Explosives, and Forensic Products targeting Homeland Security and Consumer Markets. CEO Amichai Glattstein expressed enthusiasm for the upcoming meeting, looking forward to engaging with shareholders. The company is known for its innovative products, which adhere to the stringent standards of law enforcement and security agencies.
IDenta Corp. (OTCQB: IDTA) announced a promotional campaign for its Touch&Know drug and fentanyl detection kits on American Airlines flights, reaching approximately 80,000 flights in May 2022. The CEO emphasized the importance of accessibility to quality products that can save lives. The Touch&Know kits are available for purchase on the company’s website and Amazon throughout the U.S. IDenta Corp. is recognized as a leader in developing testing kits for narcotics and explosives in the homeland security and consumer markets.
IDenta Corp. (OTCQB: IDTA), a leader in developing drug and explosive detection kits, has secured a contract to supply drug test kits to Italy's security forces. The contract follows extensive product testing, demonstrating IDenta's superior technology and pricing compared to competitors. CEO Amichai Glattstein emphasized this achievement as a significant milestone for international expansion, noting Italy's vital role in drug detection efforts. IDenta aims to enhance operations in more countries, providing innovative solutions for a safer future.
IDenta Corp. (OTCQB: IDTA) has been awarded a significant contract to supply 220,000 drug test kits to Italy's security forces after extensive testing proved their products' superiority. CEO Amichai Glattstein emphasized the importance of this achievement and the company's ongoing expansion into international markets. IDenta continues to innovate and provide advanced solutions in the drug detection sector, enhancing its competitive edge in technology and pricing.
IDenta Corp. (OTCQB: IDTA) reported its 2021 annual financial results, showing profitability amidst global challenges from the COVID pandemic. Revenue decreased by 4% to $1,392,136, while gross profit rose 12% to $1,065,965. Operating profit fell 39% to $214,151 due to new operations in the US and increased labor costs. Net profit also declined by 80% to $69,183, impacted by currency exchange rates and unforeseen tax payments. Cash and equivalents decreased to $347,151. Despite challenges, the company seeks new sales avenues and market entry.
IDenta Corp. (OTC-QB: IDTA) announces the opening of a new front office in the Washington D.C. area, marking a significant step in its operations. The office will be led by CEO Amichai Glattstein, who relocated from Israel to enhance business ties with U.S. government offices and security companies. IDenta evaluates the U.S. market potential for its detection kits at tens of millions of dollars annually, indicating strong growth prospects. This move aims to penetrate the U.S. market effectively, thereby benefiting global expansion.
IDenta Corp. (OTCQB: IDTA) reported a decline in its third quarter 2021 financial results, with revenues of $335,121, down from $496,108 in Q3 2020. Gross profit decreased to $219,286 versus $392,596 last year. Operating loss stood at $(12,177), contrasting with an operating profit of $283,232 in Q3 2020. The net loss was $(45,792), compared to net profit of $282,232 in the same period last year. Factors impacting results included project freezes due to COVID-19, new tax payments, and unfavorable exchange rates. However, the launch of online sales in the US market is expected to support future revenue growth.
IDenta Corp. (OTCQB: IDTA) has launched a unique patent kit on Amazon capable of identifying 30 types of illicit drugs with a single test, marking it as the first of its kind globally. The CEO, Amichai Glattstein, highlighted the rarity of launching a patented product on Amazon, emphasizing the significant market potential in Home Diagnostics and Drug Detection Solutions. This innovative product aims to position IDenta as a major player in the online retail market for drug detection.
IDenta Corp. (OTCQB: IDTA) has introduced a new online sales channel under the Touch&Know brand, offering home drug detection kits. This launch capitalizes on the growing demand for home diagnostic products, which surged during COVID. The retail market for household drug detection kits is estimated to be worth billions annually, positioning IDenta as a significant player. This initiative aims to provide a simple, reliable, and discreet method for consumers to identify substances in various settings, enhancing product accessibility worldwide.
IDenta Corp. (OTCQB: IDTA) released its 2021 second-quarter financial results, showing a 22% decrease in revenue, totaling $387,042 compared to $495,666 in Q2 2020. Despite lower sales, the company achieved a 17% increase in net profit, reaching $112,772. This was attributed to maintaining operational efficiency and adapting quickly to changing market conditions. Gross profit rose by 18% to $286,129, and operating profit also increased by 19% to $119,992. However, cash and cash equivalents fell to $400,704 from $639,705.
